Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 4/20 | 0.45 |
| ▸ | ACE | P12821 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 6/20 | 0.41 |
| ▸ | ITGA2 | P17301 | 6/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1252254 | 1.00 | GAA (0.62) | GAAMAPTTSHRSMN1; SMN2MME | |
| SCHEMBL2080900 | 1.00 | GAA (0.62) | GAAMAPTTSHRSMN1; SMN2MME | |
| SCHEMBL175458 | 0.85 | TSHR (0.56) | GAAMAPTTSHRSMN1; SMN2CA12 | |
| SCHEMBL17675155 | 0.83 | MAPT (0.46) | GAAMAPTTSHRSMN1; SMN2MME | |
| SCHEMBL26780543 | 0.82 | TSHR (0.57) | GAAMAPTTSHRSMN1; SMN2CA12 | |
| SCHEMBL26780545 | 0.82 | TSHR (0.57) | GAAMAPTTSHRSMN1; SMN2CA12 | |
| SCHEMBL26782214 | 0.82 | TSHR (0.57) | GAAMAPTTSHRSMN1; SMN2CA12 | |
| SCHEMBL1252496 | 0.81 | TSHR (0.55) | GAAMAPTTSHRSMN1; SMN2CA12 | |
| SCHEMBL1252495 | 0.81 | TSHR (0.55) | GAAMAPTTSHRSMN1; SMN2CA12 | |
| SCHEMBL3292759 | 0.80 | MAPT (0.48) | GAAMAPTTSHRSMN1; SMN2MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024085695-A1 | NOVEL ALTIRATINIB DERIVATIVE, MANUFACTURING METHOD THEREFOR, AND COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION, ALLEVIATION, OR TREATMENT OF SKIN PIGMENTATION | 재단법인 아산사회복지재단 | 2024-04-25 | — | — | WO | disclosed |
| EP-1675859-B1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-05 | — | — | EP | disclosed |
| US-20110038835-A1 | ANILIDES AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-02-17 | — | — | US | disclosed |
| EP-2234487-A1 | ANILIDES AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009079009-A1 | ANILIDES AND ANALOGS AS RHO KINASE INHIBITORS | FENG YANGBO (US) | 2009-06-25 | — | — | WO | disclosed |
| EP-1835934-A2 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2007-09-26 | — | — | EP | disclosed |
| US-7244843-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| WO-2006071940-A2 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-07-06 | — | — | WO | disclosed |
| EP-1675859-A1 | MODULATORS OF SEROTONIN RECEPTORS | Bristol-Myers Squibb Company (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005035533-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-21 | — | — | WO | disclosed |
| US-5620987-A | Amino acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 1997-04-15 | — | — | US | disclosed |
| US-5554756-A | PROTEASE INHIBITOR | HOFFMANN-LA ROCHE INC. (US) | 1996-09-10 | — | — | US | disclosed |
| US-5446161-A | Protease inhibitor, viricides | HOFFMANN-LA ROCHE INC. (US) | 1995-08-29 | — | — | US | disclosed |
| US-5430023-A | Tripeptide antithrombotic agents | ELI LILLY AND COMPANY (US) | 1995-07-04 | — | — | US | disclosed |
| EP-0346847-B1 | Amino acid derivatives | HOFFMANN LA ROCHE (CH) | 1994-05-11 | — | — | EP | disclosed |
| US-5157041-A | Viricides | HOFFMANN-LA ROCHE INC. (US) | 1992-10-20 | — | — | US | disclosed |
| EP-0346847-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-12-20 | — | — | EP | disclosed |
| US-4537967-A | ANGIOTENSIN COVERTING ENZYME INHIBITORS | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1985-08-27 | — | — | US | disclosed |
| US-4537967-A | ANGIOTENSIN COVERTING ENZYME INHIBITORS | WAKAMOTO PHARMACEUTICAL CO., LTD. (JP) | 1985-08-27 | — | — | US | disclosed |
| US-3928612-A | 1,2-Dihydro- and 1,2,3,4-tetrahydro-1-oxo-3-isoquinolinecarboxylic acid derivatives as anti-allergic agents | AMERICAN HOME PROD | 1975-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110038835-A1 | ANILIDES AND ANALOGS AS RHO KINASE INHIBITORS | ROCK1, RHOA, ROCK2 | GAA 995/4885MAPT 3009/4885TSHR 3961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.